NCT04056975UnknownPhase 1
A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
EVIVE Biotechnology0 sites54 target enrollmentStarted: September 15, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 54
- Primary Endpoint
- Evaluate the Incidence and Characteristics of SAE of A-319 Treat on Relapsed or Refractory B-cell Lymphoma
Study Overview
Brief Summary
Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Detailed Description
Protocol Number: SP071744 Study Stage: Phase I Study Number: 1 site Subject Number: up to 54 patients with Relapsed or Refractory B-cell Lymphoma
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18-75 years, all genders
- •Patients with definite B-cell Lymphoma, includes FL, MZL, MCL, DLBCL.
- •Patients With Relapsed or Refractory B-cell Lymphoma
- •Lesions are measurable in 21 days before treatment
- •Normal bone marrow function
- •Normal liver, kidney, lung and heart function
- •the Subjects can sign the ICF and obey the protocol, elsewise, his/her guardian should sign
- •Life expectancy is at least 3 months
Exclusion Criteria
- •Past or present CNS disease
- •Associated with lymphoma by the infiltrates of CNS
- •A history of autoimmune disease with CNS involvement or autoimmune disease
- •Previous history of autoimmune disease or other malignancy
- •A history of deep venous thrombosis or pulmonary embolism
- •Auto-HSCT was performed within 12 weeks prior to initiation of treatment
- •Previous organ transplantation or allogeneic hematopoietic stem cell transplantation
- •The Investigator determined that the patients were associated with a disease, medical condition, or social factor that might affect study results or compliance
- •Immunosuppressant are being used
- •Radiotherapy was given within 6 weeks prior to A-319 treatment
- •Chemotherapy, immunotherapy and targeted therapy were received within 4 weeks before A-319 treatment
- •Previous CAR-T cell therapy
- •Received anti-lymphoma drugs in the first 4 weeks of A-319 treatment
- •There was no recovery of toxic effects (CTCAE> grade 1 adverse events) at the last treatment, except hair loss
- •Those who underwent major surgery 28 days before enrollment (excluding lymph node biopsy);Or plan to operate during the study period
- •Those who had received active/attenuated live vaccine within 28 days prior to screening
- •For pregnant (positive pregnancy test) and lactating women, those of childbearing age who signed the informed consent form and did not agree to use contraception for at least 3 months after the end of the study;Within 7 days prior to the first day of treatment, women of childbearing age require a positive serum pregnancy test (HCG)
- •Male patients who signed informed consent forms and did not agree to use contraception for at least 3 months at the end of the study (except surgical sterilization)
- •Known allergy to immunoglobulin or research drugs and their excipients
- •Patients considered unfit to participate in the study
Outcomes
Primary Outcomes
Evaluate the Incidence and Characteristics of SAE of A-319 Treat on Relapsed or Refractory B-cell Lymphoma
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
Incidence and Characteristics of SAE
Evaluate the MTD and DLT of A-319 Treat on Relapsed or Refractory B-cell Lymphoma
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
dose limited toxicity(DLT), maximum tolerance dose(MTD)
Secondary Outcomes
- Evaluate the PK(Tmax) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma(At the end of Cycle3 (each cycle is 28 days))
- Evaluate the PK(T1/2) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma(At the end of Cycle3 (each cycle is 28 days))
- Evaluate the PK(CL) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma(At the end of Cycle3 (each cycle is 28 days))
- Evaluate the PK(Cmax) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma(At the end of Cycle3 (each cycle is 28 days))
- Evaluate the PD of A-319 Treat on Relapsed or Refractory B-cell Lymphoma(At the end of Cycle3 (each cycle is 28 days))
- Evaluate the PK(AUC) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma(At the end of Cycle3 (each cycle is 28 days))
- Evaluate the PK(Vz) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma(At the end of Cycle3 (each cycle is 28 days))
Investigators
Similar Trials
Terminated
Phase 1
AHN-12 Biodistribution in Advanced LeukemiaAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelogenous LeukemiaNCT01207076Masonic Cancer Center, University of Minnesota8
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)Relapsed Malignant Solid NeoplasmNCT05865002Aurigene Discovery Technologies Limited50
Unknown
Phase 1
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast CancerBreast CancerNCT01304797Merrimack Pharmaceuticals75
Completed
Early Phase 1
An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant TumorsMalignant TumorsNCT01678690InnoPharmax Inc.11
Completed
Phase 1
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableNon-Hodgkin's Lymphoma, Solid CancersNCT00876122Genentech, Inc.60